Table 2.
Proliferation and migration of endothelial cells in response to CM from ovarian cancer cells pre-incubated with CM from senescent HPMCs in which individual proteins were neutralized
| Neutralized mediator | HUVEC proliferation | HUVEC migration | ||||
|---|---|---|---|---|---|---|
| A2780 | OVCAR-3 | SKOV-3 | A2780 | OVCAR-3 | SKOV-3 | |
| CXCL1 | 104 ± 5 | 111 ± 3 | 124 ± 12 | 105 ± 6 | 89 ± 11 | 89 ± 21 |
| CXCL8 | 92 ± 6 | 92 ± 8 | 100 ± 4 | 103 ± 5 | 101 ± 8 | 102 ± 6 |
| IL-6 | 72 ± 3* | 64 ± 5* | 68 ± 2* | 64 ± 6* | 81 ± 4* | 78 ± 2* |
| PAI-1 | 113 ± 22 | 115 ± 21 | 104 ± 5 | 101 ± 1 | 105 ± 9 | 106 ± 6 |
| u-PA | 92 ± 11 | 95 ± 7 | 99 ± 1 | 98 ± 12 | 95 ± 5 | 101 ± 3 |
| sICAM-1 | 107 ± 2 | 110 ± 8 | 96 ± 16 | 102 ± 11 | 103 ± 4 | 100 ± 8 |
| TGF-β1 | 84 ± 5* | 81 ± 2* | 87 ± 4* | 84 ± 2* | 88 ± 1* | 103 ± 8 |
| TSP-1 | 106 ± 12 | 102 ± 5 | 102 ± 3 | 101 ± 1 | 112 ± 5 | 102 ± 7 |
| VEGF | 96 ± 3 | 91 ± 8 | 106 ± 8 | 98 ± 2 | 101 ± 1 | 92 ± 9 |
The values are expressed as a percentage of endothelial cell proliferation/migration upon incubation with CM from cancer cells pre-treated with an intact CM from senescent HPMCs (considered as 100 %). Please note that the neutralization of IL-6 and TGF-β1 decreased both the proliferation and migration of endothelial cells to a level characterizing their behavior upon exposure to CM generated by cancer cells pre-incubated with an autologous CM. The concentrations of all antibodies used here are provided in the "Materials and methods" section. The results derive from experiments performed with CM produced by HPMCs from 8 different donors. Cancer cells and endothelial cells were used in hexaplicates. The asterisks indicate a significant decrease in endothelial cell proliferation/migration